medigraphic.com
ISSN 1561-302X (Print)

2022, Number 4

<< Back Next >>

Rev cubana med 2022; 61 (4)

Effectiveness and safety of the use of colchicine to control inflammation in atherosclerosis

León-Cardona L, Zapata-Montealegre C, Moreno-Gómez F

Language: Spanish
References: 36
Page: 1-24
PDF size: 500.77 Kb.


ABSTRACT

Introduction: Currently, there is no direct pharmacological strategy to mediate the inflammation generated in atherosclerosis in the treatment of atherosclerotic disease.
Objective: To identify the level of effectiveness and safety of the use of colchicine to control inflammation in atherosclerosis.
Methods: A systematized search of the MEDLINE bibliographic database was performed through PubMed, divided into three search segments with MeSH terms. Titles and abstracts were reviewed to select 29 articles.
Results: Colchicine was shown to be a drug with effect in decreasing inflammation in atherosclerosis and inflammatory and metabolic cytokine production, targeting NLRP3 inflammasome blockade and mediating levels of acute-phase proteins such as high-sensitivity C-reactive protein (h-CRP). Colchicine was shown to have no significant effect on other lipoprotein subfractions. In terms of safety long-term colchicine is well tolerated at doses <1mg/day reported gastrointestinal intolerances as the most common side effect.
Conclusions: Colchicine is effective in mediating inflammation in atherosclerotic disease. Additionally it has an optimal safety role reported only gastrointestinal adverse effects, making it an attractive strategy for mediating inflammation in atherosclerotic disease.


REFERENCES

  1. Katzung B. Farmacología básica y clínica. Decimocuarta edición. México: McGraw-Hill; 2020.

  2. Firestein G, Kelley W. Tratado de reumatología. Décima edición. Barcelona: Elsevier; 2018.

  3. Goldman L, Schafer A. Goldman-Cecil. Tratado de medicina Interna. Vigesimoquinta edición. Barcelona: Elsevier; 2017.

  4. Butt AK, Cave B, Maturana M, Towers WF, Khouzam R. N (2021). The Role of Colchicine in Coronary Artery Disease. Current Problems in Cardiology. 2021;46(3): 100690. DOI: https://doi:10.1016/j.cpcardiol.2020.100690

  5. Thompson PL, Nidorf SM. Colchicine: an affordable anti-inflammatory agent for atherosclerosis. Current Opinion in Lipidology, 2018;29(6):467-73. DOI: https://doi:10.1097/MOL.0000000000000552

  6. National Institute for Health and Care Excellence. Acute coronary syndromes. NICE Guideline 185. London; 2020.

  7. Cross S. Underwood's pathology. 7th ed. New York: ELSEVIER; 2018.

  8. Leiva E. Epidemiología del síndrome coronario agudo y la insuficiencia cardíaca en Latinoamérica. Rev. Esp. Cardiol. 2011;64(Supl 2):34-43.

  9. Nidorf SM, Thompson PL. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Clinical Therapeutics. 2018;41(1):41-8. DOI: https://doi:10.1016/j.clinthera.2018.11.016

  10. Vaidya K, Martínez G, Patel S. The Role of Colchicine in Acute Coronary Syndromes. Clin Ther. 2019;41(1):11-20. DOI: https://doi: 10.1016/j.clinthera.2018.07.023

  11. Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in Stable Coronary Artery Disease. Clin Ther. 2019;41(1):30-40. DOI: https://doi:10.1016/j.clinthera.2018.09.011

  12. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis. 2012;33(1):88-94. DOI: https://doi:10.1007/s11239-011-0637-y

  13. Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc. 2015;4(8):e002128. DOI: https://doi:10.1161/JAHA.115.002128

  14. Nidorf SM, Eikelboom JW, Thompson PL. Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. Journal of Cardiov Pharmacol and Therapeutics. 2013;19(1):45-52. DOI: https://doi:10.1177/1074248413499972

  15. Nidorf S, Eikelboom J, Thompson P. Colchicine for Secondary Prevention of Cardiovascular Disease. Current Atherosclerosis Reports. 2014;16(391):1-8. DOI: https://doi:10.1007/s11883-013-0391-z

  16. Gasparyan A, Ayvazyan L, Yessirkepov M, Kitas G. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opinion on Drug Metabolism & Toxicology. 2015;11(11):1-14. DOI: https://doi:10.1517/17425255.2015.1076391

  17. Khan R, Spagnoli V, Tardif J, L'Allier P. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Atherosclerosis. 2015;240(2):497-509. DOI: https://doi:10.1016/j.atherosclerosis.2015.04.783

  18. Imazio M, Gaita F. Colchicine for cardiovascular medicine. Future Cardiology. 2016;12(1):9-16. DOI: https://doi:10.2217/fca.15.59

  19. Leung Y, Yao Hui L, Kraus V. Colchicine. Update on mechanisms of action and therapeutic uses. Seminars in Arthritis and Rheumatism. 2015;45(3):341-50. DOI: https://doi:10.1016/j.semarthrit.2015.06.013

  20. Slobodnick A, Shah B, Pillinger M, Krasnokutsky S. Colchicine: Old and New. The American Journal of Medicine. 2015;128(5):461-70. DOI: https://doi:10.1016/j.amjmed.2014.12.010

  21. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262-71. DOI: https://doi:10.1016/j.atherosclerosis.2017.12.027

  22. Spartalis M, Spartalis E, Tzatzaki E, Tsilimigras D, Moris D, Kontogiannis C; et al. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. Cardiovascular & Hematological Agents In Medicinal Chemistry. 2018;16(2):74-80. DOI: https://doi:10.2174/1871525717666181211110332

  23. Khambhati J, Engels M, Allard-Ratick M, Sandesara P, Quyyumi A, Sperling L. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018;276:1-9. DOI: https://doi:10.1016/j.atherosclerosis.2018.07.007

  24. Tucker B, Kurup R, Barraclough J, Henriquez R, Cartland S, Arnott C, et al. Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study. Clin Ther. 2019;41(10):2172-81. DOI: https://doi:10.1016/j.clinthera.2019.07.015

  25. Nidorf SM, Fiolet ATL, Eikelboom JW, Schut A, Opstal TSJ, Bax WA et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46-56. DOI https://doi:10.1016/j.ahj.2019.09.011

  26. Demidowich AP, Wolska A, Wilson SR, Levine JA, Sorokin AV, Brady SM, et al. Colchicine's effects on lipoprotein particle concentrations in adults with metabolic syndrome: A secondary analysis of a randomized controlled trial. J Clin Lipidol. 2019;13(6):1016-22.e2. DOI: https://doi:10.1016/j.jacl.2019.10.011

  27. Arbel Y, Abuzeid W, Rosenson R, Weisman A, Farkouh M. Old Drugs for New Indications in Cardiovascular Medicine. Cardiovascular Drugs and Therapy. 2018;32(2):223-32. DOI: https://doi:10.1007/s10557-018-6785-y

  28. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-505. DOI: https://doi:10.1056/NEJMoa1912388

  29. Demidowich AP, Levine JA, Apps R, Cheung FK, Chen J, Fantoni G; et al. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. Int J Obes (Lond). 2020;44(8):1793-9. DOI: https://doi:10.1038/s41366-020-0598-3

  30. Tousoulis D, Oikonomou E, Economou E, Crea F, Kaski J. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal. 2016;37(22):1-13. DOI: https://doi: doi:10.1093/eurheartj/ehv759

  31. Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart. 2016;102(8):590-6. DOI: https://doi:10.1136/heartjnl-2015-308542

  32. Kajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol. 2019;281:35-9. DOI: https://doi:10.1016/j.ijcard.2019.01.054

  33. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. DOI: https://doi:10.1186/s13075-020-2120-7

  34. Masson W, Lobo M, Molinero G, Masson G, Lavalle-Cobo A. Role of Colchicine in Stroke Prevention: An Updated Meta-Analysis. J Stroke Cerebrovasc Dis. 2020;29(5):104756. DOI: https://doi:10.1016/j.jstrokecerebrovasdis.2020.104756

  35. Khandkar C, Vaidya K, Patel S. Colchicine for Stroke Prevention: A Systematic Review and Meta-analysis. Clin Ther. 2019;41(3):582-90.e3. DOI: https://doi:10.1016/j.clinthera.2019.02.003

  36. Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Imaging. 2018;11(2):305-16. DOI: https://doi:10.1016/j.jcmg.2017.08.013




2020     |     www.medigraphic.com